Abstract
Evolution in the treatment of multiple myeloma and impact on dialysis independence: data from a French cohort from 1999 to 2014
Highlights
Renal impairment is a frequent complication in patients with multiple myeloma (MM) with an important impact on survival.[1,2] It is found in 20–40% of cases at diagnosis and in almost 50% in the disease course
Bortezomib used in combination with melphalan and prednisone as a first line CT leads to a shorter renal recovery when compared with melphalan plus prednisone.[7]
We found 135 patients admitted to our Nephrology unit between 1999 and 2014 with the diagnosis of MM and acute renal failure
Summary
Renal impairment is a frequent complication in patients with multiple myeloma (MM) with an important impact on survival.[1,2] It is found in 20–40% of cases at diagnosis and in almost 50% in the disease course. Bortezomib used in combination with melphalan and prednisone as a first line CT leads to a shorter renal recovery when compared with melphalan plus prednisone.[7] Dimopoulos et al.[8] have shown an increased survival in patients with renal involvement with the advent of novel therapies, but included only a few dialysis-dependent patients. Patients were included in the analysis if they responded to the following criteria: age between 18 and 90, diagnosis of MM according to the International Myeloma Working Group criteria and renal involvement (RI) defined by a rise in creatinine above 177 μmol/l (42 mg/dl),[9] absence of amyloid light-chain amyloidosis or significant albuminuria, a previous normal renal function or chronic kidney disease from another cause.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
